{
  "created_at": "Thu Jul 08 14:30:1 +0000 2021",
  "id_str": "1413127316117590016",
  "full_text": "China’s Sinopharm and Sinovac look like being a large part of the world’s vaccine supply for the rest of the year. But there are some doubts about their efficacy, especially against new variants https://t.co/OvgoaiYvwv",
  "display_text_range": [
    0,
    218
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/OvgoaiYvwv",
        "expanded_url": "https://econ.st/3yBEeYd",
        "display_url": "econ.st/3yBEeYd",
        "indices": [
          195,
          218
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 46,
  "favorite_count": 67,
  "possibly_sensitive": false,
  "original_created_at": "Thu Jul 08 13:26:21 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "中国のSinopharm社とSinovac社は、今年の残りの期間、世界のワクチン供給の大部分を担っているように見える。しかし、その効果については、特に新種のウイルスに対する効果に疑問があります。https://t.co/OvgoaiYvwv"
    },
    {
      "locale": "zh",
      "full_text": "中国的国药集团和Sinovac看起来是今年剩余时间里世界疫苗供应的很大一部分。但是人们对它们的效力有一些怀疑，特别是对新变种https://t.co/OvgoaiYvwv"
    },
    {
      "locale": "zh-Hant",
      "full_text": "中國的國藥集團和Sinovac看起來是今年剩餘時間裏世界疫苗供應的很大一部分。但是人們對它們的效力有一些懷疑，特別是對新變種https://t.co/OvgoaiYvwv"
    }
  ]
}